Neuroimaging and neurophysiologic biomarkers for diagnosis and prognosis of depressive disorders, bipolar disorder, anxiety disorders, obsessive compulsive disorder, posttraumatic stress disorder, and substance use disorder: an evidence map - Summary - MDSpire
Advertisement
Neuroimaging and neurophysiologic biomarkers for diagnosis and prognosis of depressive disorders, bipolar disorder, anxiety disorders, obsessive compulsive disorder, posttraumatic stress disorder, and substance use disorder: an evidence map
To summarize the current evidence on the use of neuroimaging and neurophysiological biomarkers in diagnosing and treating various psychiatric disorders, with a focus on diagnosis and prognosis.
Key Findings:
Advancements in precision medicine have focused on identifying biomarkers for psychiatric disorders, including specific neuroimaging techniques.
Large-scale studies like the UK Biobank are ongoing to enhance understanding of neuroimaging biomarkers.
Clinical application of neuroimaging techniques faces challenges due to heterogeneity in psychiatric disorders.
Interpretation:
The evidence map highlights the potential of neuroimaging and neurophysiological biomarkers in improving diagnosis and treatment of psychiatric disorders, but significant gaps and challenges remain, which have important implications for future research.
Limitations:
Clinical heterogeneity and symptom overlap among psychiatric disorders complicate the application of findings, affecting the robustness of conclusions.
The reliance on exploratory studies limits the robustness of conclusions drawn from the evidence map.
Conclusion:
Further research and larger studies are necessary to translate neuroimaging and neurophysiological findings into clinical practice for mental health disorders, particularly focusing on addressing identified gaps.
by Catherine Sowerby, Adrienne Landsteiner, Kristen Ullman, Maylen Anthony, Caleb Kalinowski, Michele R. Spoont, Scott Sponheim, Kelvin Lim, Jose V. Pardo, Timothy J. Wilt, Wei Duan-Porter
A narrative review outlines screening pathways, diagnostic challenges, and treatment strategies, including integrated care models and medication selection.
